In summary, the present study revealed AT-II mitigates ER stress-related fatty liver disease through targeting the FXR-SERCA2-eIF2α signaling pathway, and emphasized the importance of the interplay between FXR and ER stress in controlling NAFLD. Here, ATP2A2 is linked to metabolic dysfunction-associated steatotic liver disease.